Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis

Proteomics - Clinical Applications

Volumn 3, Issue 11, 2009, Pages 1273-1287

  Jastorff, Archana M ^a,b   Haegler, Katrin ^a   Maccarrone, Giuseppina ^a   Holsboer, Florian ^a   Weber, Frank ^a   Ziemssen, Tjalf ^c   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neurodegeneration; Protein phosphorylation; Sirtuin; Stathmin 1

Indexed keywords

CHLORIDE CHANNEL; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CREATINE KINASE BB; PROTEOME; SERUM AMYLOID P; SIRTUIN 2; STATHMIN;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; MOLECULAR MECHANICS; MOUSE; MULTIPLE SCLEROSIS; MYELINATION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SPINAL CORD;

ANIMALIA; MURINAE;

EID: 77951063747     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200800155     Document Type: Article

References (60)

1. Steinman, L., Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2, 762-764.
2. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R. et al., Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278-285.
3. Waxman, S.G., Multiple sclerosis as a neuronal disease. Arch. Neurol. 2000, 57, 22-24.
4. Kornek, B., Storch, M.K., Weissert, R., Wallstroem, E. et al., Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157, 267-276.
5. Trapp, B.D., Ransohoff, R., Rudick, R., Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 1999, 12, 295-302.
6. Prat, A., Antel, J., Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 2005, 18, 225-230.
7. Waxman, S.G., Do "demyelinating" diseases involve more than myelin? Nat. Med. 2000, 6, 738-739.
8. Murray, T.J., Diagnosis and treatment of multiple sclerosis. Br. Med. J. 2006, 332, 525-527.
9. Bielekova, B., Martin, R., Development of biomarkers in multiple sclerosis. Brain 2004, 127, 1463-1478.
10. Robinson, W.H., Utz, P.J., Steinman, L., Genomic and proteomic analysis of multiple sclerosis - opinion. Curr. Opin. Immunol. 2003, 15, 660-667.
11. Chabas, D., Baranzini, S.E., Mitchell, D., Bernard, C.C. et al., The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294, 1731-1735.
12. Lock, C., Hermans, G., Pedotti, R., Brendolan, A. et al., Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8, 500-508.
13. Ibrahim, S.M., Mix, E., Bottcher, T., Koczan, D. et al., Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001, 124, 1927-1938.
14. Steinman, L., Zamvil, S., Transcriptional analysis of targets in multiple sclerosis. Nat. Rev. Immunol. 2003, 3, 483-492.
15. Fountoulakis, M., Kossida, S., Proteomics-driven progress in neurodegeneration research. Electrophoresis 2006, 27, 1556-1573.
16. Ibrahim, S.M., Gold, R., Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr. Opin. Neurol. 2005, 18, 231-235.
17. Turck, C.W., Maccarrone, G., Sayan-Ayata, E., Jacob, A.M. et al., The quest for brain disorder biomarkers. J. Med. Invest. 2005, 52, 231-235.
18. Alt, C., Duvefelt, K., Franzen, B., Yang, Y., Engelhardt, B., Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57Bl/6 and SJL mice. Brain Pathol. 2005, 15, 1-16.
19. Duzhak, T., Emerson, M.R., Chakrabarty, A., Alterman, M.A., Levine, S.M., Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell. Mol. Biol. 2003, 49, 723-732.
20. Liu, T., Donahue, K.C., Hu, J., Kurnellas, M.P. et al., Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6, 2565-2575.
21. Dumont, D., Noben, J.P., Raus, J., Stinissen, P., Robben, J., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
22. Hammack, B.N., Fung, K.Y., Hunsucker, S.W., Duncan, M.W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
23. Noben, J.P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
24. Han, M.H., Hwang, S.I., Roy, D.B., Lundgren, D.H. et al., Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 28, 1076-1081.
25. McGeer, E.G., Yasojima, K., Schwab, C., McGeer, P.L., The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging 2001, 22, 843-848.
26. Kalaria, R.N., Galloway, P.G., Perry, G., Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol. Appl. Neurobiol. 1991, 17, 189-201.
27. Botto, M., Hawkins, P.N., Bickerstaff, M.C., Herbert, J. et al., Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 1997, 3, 855-859.
28. Urbanyi, Z., Lakics, V., Erdo, S.L., Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex. Eur. J. Pharmacol. 1994, 270, 375-378.
29. Urbanyi, Z., Laszlo, L., Tomasi, T.B., Toth, E. et al., Serum amyloid P component induces neuronal apoptosis and betaamyloid immunoreactivity. Brain Res. 2003, 988, 69-77.
30. Garlanda, C., Bottazzi, B., Bastone, A., Mantovani, A., Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 2005, 23, 337-366.
31. Kalaria, R.N., Golde, T.E., Cohen, M.L., Younkin, S.G., Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann. NY Acad. Sci. 1991, 640, 145-148.
32. Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887, 80-89.
33. Styren, S.D., Kamboh, M.I., DeKosky, S.T., Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J. Comp. Neurol. 1998, 396, 511-520.
34. Combs, C.K., Karlo, J.C., Kao, S.C., Landreth, G.E., beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 2001, 21, 1179-1188.
35. Schlichter, L.C., Sakellaropoulos, G., Ballyk, B., Pennefather, P.S., Phipps, D.J., Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells. Glia 1996, 17, 225-236.
36. Novarino, G., Fabrizi, C., Tonini, R., Denti, M.A. et al., Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J. Neurosci. 2004, 24, 5322-5330.
37. Perluigi, M., Poon, H.F., Maragos, W., Pierce, W.M. et al., Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics 2005, 4, 1849-1861.
38. Choi, J., Forster, M.J., McDonald, S.R., Weintraub, S.T. et al., Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. Free Radic. Biol. Med. 2004, 36, 1155-1162.
39. Vassilopoulos, D., Jockers-Wretou, E., Serum creatine kinase B levels in diseases of the central nervous system. Eur. Neurol. 1987, 27, 78-81.
40. Dutta, R., McDonough, J., Yin, X., Peterson, J. et al., Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59, 478-489.
41. Wallimann, T., Dolder, M., Schlattner, U., Eder, M. et al., Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 1998, 8, 229-234.
42. Dedeoglu, A., Kubilus, J.K., Yang, L., Ferrante, K.L. et al., Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 2003, 85, 1359-1367.
43. Arimura, N., Menager, C., Kawano, Y., Yoshimura, T. et al., Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol. Cell. Biol. 2005, 25, 9973-9984.
44. Quinn, C.C., Gray, G.E., Hockfield, S., A family of proteins implicated in axon guidance and outgrowth. J. Neurobiol. 1999, 41, 158-164.
45. Zhang, Z.O.A., Sadasivan, S., Kobeissy, F.H., Fang, T. et al., Calpain-mediated collapsin responsemediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J. Neurotrauma. 2007, 24, 460-472.
46. Touma, E.K.S., Fukui, K., Koike, T., Calpain-mediated cleavage of collapsin response mediator protein(CRMP)-2 during neurite degeneration in mice. Eur. J. Neurosci. 2007, 26, 3368-3381.
47. Mori, N., Morii, H., SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. J. Neurosci. Res. 2002, 70, 264-273.
48. Grenningloh, G., Soehrman, S., Bondallaz, P., Ruchti, E., Cadas, H., Role of the microtubule destabilizing proteins SCG10 and stathmin in neuronal growth. J. Neurobiol. 2004, 58, 60-69.
49. Sobel, A., Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem. Sci. 1991, 16, 301-305.
50. Horwitz, S.B., Shen, H.J., He, L., Dittmar, P. et al., The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J. Biol. Chem. 1997, 272, 8129-8132.
51. Southwood, C.M.P. M., Dryden, S., Tainsky, M.A., Gow, A., Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem. Res. 2007, 32, 187-195.
52. Liu, A., Stadelmann, C., Moscarello, M., Bruck, W. et al., Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. J. Neurosci. 2005, 25, 737-747.
53. Frye, R.A., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273, 793-798.
54. North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., Verdin, E., The human Sir2 ortholog, SIRT2, is an NAD1-dependent tubulin deacetylase. Mol. Cell. 2003, 11, 437-444.
55. Mattson, M.P., Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res. Rev. 2003, 2, 329-342.
56. Morales, M., Fifkova, E., Distribution of acetylated alphatubulin in brain. In situ localization and biochemical characterization. Cell Tissue Res. 1991, 265, 415-423.
57. Araki, T., Sasaki, Y., Milbrandt, J., Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration [see comment]. Science 2004, 305, 1010-1013.
58. Hisahara, S., Chiba, S., Matsumoto, H., Horio, Y., Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2alpha). J. Pharmacol. Sci. 2005, 98, 200-204.
59. Porcu, M., Chiarugi, A., The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 2005, 26, 94-103.
60. Almeras, L., Lefranc, D., Drobecq, H., de Seze, J. et al., New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004, 4, 2184-2194.